Board member buys additional shares in Scandinavian ChemoTech AB
Scandinavian ChemoTech AB (publ) (“ChemoTech”) announces that Martin Jerndal, board member, bought further 5,000 shares on the 12th of November 2021 for approximately SEK 84,600 over the stock exchange. His total holding now amounts to 587,695 shares in ChemoTech.
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: firstname.lastname@example.org
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.